Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”
Executive Summary
GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses
You may also be interested in...
GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO
GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry
GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO
GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry
Aranesp Bad Luck Catches Up To Amgen, Forces Pharma-Style Reorganization
As Amgen enters into a major restructuring effort that will include extensive cost-cutting and significant headcount reductions, it will also make serious adjustments to its R&D program - including scaling back from its industry-leading approach of investing a high percentage of sales on R&D